Gene therapy for sickle cell disease

2.

Tisdale

JF

,

Thein

SL

,

Eaton

WA

.

Treating sickle cell anemia

.

Science

.

2020

;

367

(

6483

):

1198

-

1199

.

doi:10.1126/science.aba3827

.

3.

Lanzkron

S

,

Carroll

CP

,

Haywood

C.

Mortality rates and age at death from sickle cell disease: U.S., 1979–2005

.

Public Health Rep

.

2013

;

128

(

2

):

110

-

116

.

doi:10.1177/003335491312800206

.

4.

Rogers

S

,

Pfuderer

P.

Use of viruses as carriers of added genetic information

.

Nature

.

1968

;

219

(

5155

):

749

-

751

.

doi:10.1038/219749a0

.

5.

Mercola

KE

,

Cline

MJ

.

Sounding boards. The potentials of inserting new genetic information

.

N Engl J Med

.

1980

;

303

(

22

):

1297

-

1300

.

doi:10.1056/NEJM198011273032211

.

6.

Rosenberg

SA

,

Aebersold

P

,

Cornetta

K

, et al.

Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

.

N Engl J Med

.

1990

;

323

(

9

):

570

-

578

.

doi:10.1056/NEJM199008303230904

.

7.

Boztug

K

,

Schmidt

M

,

Schwarzer

A

, et al.

Stem-cell gene therapy for the Wiskott-Aldrich syndrome

.

N Engl J Med

.

2010

;

363

(

20

):

1918

-

1927

.

doi:10.1056/NEJMoa1003548

.

8.

Braun

CJ

,

Boztug

K

,

Paruzynski

A

, et al.

Gene therapy for Wiskott- Aldrich syndrome—long-term efficacy and genotoxicity

.

Sci Transl Med

.

2014

;

6

(

227

):

227ra33

.

doi:10.1126/scitranslmed.3007280

.

9.

Hacein-Bey-Abina

S

,

Garrigue

A

,

Wang

GP

, et al.

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

.

J Clin Invest

.

2008

;

118

(

9

):

3132

-

3142

.

doi:10.1172/JCI35700

.

10.

Chandrakasan

S

,

Malik

P.

Gene therapy for hemoglobinopathies: the state of the field and the future

.

Hematol Oncol Clin North Am

.

2014

;

28

(

2

):

199

-

216

.

doi:10.1016/j.hoc.2013.12.003

.

11.

May

C

,

Rivella

S

,

Callegari

J

, et al.

Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin

.

Nature

.

2000

;

406

(

6791

):

82

-

86

.

doi:10.1038/35017565

.

12.

May

C

,

Rivella

S

,

Chadburn

A

,

Sadelain

M.

Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene

.

Blood

.

2002

;

99

(

6

):

1902

-

1908

.

doi:10.1182/blood.v99.6.1902

.

13.

Pawliuk

R

,

Westerman

KA

,

Fabry

ME

, et al.

Correction of sickle cell disease in transgenic mouse models by gene therapy

.

Science

.

2001

;

294

(

5550

):

2368

-

2371

.

doi:10.1126/science.1065806

.

14.

Levasseur

DN

,

Ryan

TM

,

Pawlik

KM

,

Townes

TM

.

Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells

.

Blood

.

2003

;

102

(

13

):

4312

-

4319

.

doi:10.1182/blood-2003-04-1251

.

15.

Jinek

M

,

Chylinski

K

,

Fonfara

I

,

Hauer

M

,

Doudna

JA

,

Charpentier

E.

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity

.

Science

.

2012

;

337

(

6096

):

816

-

821

.

doi:10.1126/science.1225829

.

16.

Cavazzana-Calvo

M

,

Payen

E

,

Negre

O

, et al.

Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

.

Nature

.

2010

;

467

(

7313

):

318

-

322

.

doi:10.1038/nature09328

.

17.

Ribeil

J-A

,

Hacein-Bey-Abina

S

,

Payen

E

, et al.

Gene therapy in a patient with sickle cell disease

.

N Engl J Med

.

2017

;

376

(

9

):

848

-

855

.

doi:10.1056/NEJMoa1609677

.

18.

Thompson

AA

,

Walters

MC

,

Kwiatkowski

J

, et al.

Gene therapy in patients with transfusion-dependent β-thalassemia

.

N Engl J Med

.

2018

;

378

(

16

):

1479

-

1493

.

doi:10.1056/NEJMoa1705342

.

19.

Locatelli

F

,

Thompson

AA

,

Kwiatkowski

JL

, et al.

Betibeglogene autotemcel gene therapy for non-beta(0)/beta(0) genotype beta-thalassemia

.

N Engl J Med

.

2022

;

386

(

5

):

415

-

427

.

doi:10.1056/NEJMoa2113206

.

20.

Kanter

J

,

Thompson

AA

,

Pierciey

FJ

Jr, et al.

Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study

.

Am J Hematol

.

2023

;

98

(

1

):

11

-

22

.

doi:10.1002/ajh.26741

.

21.

Uchida

N

,

Leonard

A

,

Stroncek

D

, et al.

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor

.

Haematologica

.

2020

;

105

(

10

):

e497

.

doi:10.3324/haematol.2019.236182

.

22.

Boulad

F

,

Shore

T

,

van Besien

K

, et al.

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results

.

Haematologica

.

2018

;

103

(

5

):

770

-

777

.

doi:10.3324/haematol.2017.187047

.

23.

Esrick

EB

,

Manis

JP

,

Daley

H

, et al.

Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients

.

Blood Adv

.

2018

;

2

(

19

):

2505

-

2512

.

doi:10.1182/bloodadvances.2018016725

.

24.

Lagresle-Peyrou

C

,

Lefrère

F

,

Magrin

E

, et al.

Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion

.

Haematologica

.

2018

;

103

(

5

):

778

-

786

.

doi:10.3324/haematol.2017.184788

.

25.

Kanter

J

,

Walters

MC

,

Krishnamurti

L

, et al.

Biologic and clinical efficacy of LentiGlobin for sickle cell disease

.

N Engl J Med

.

2022

;

386

(

7

):

617

-

628

.

doi:10.1056/NEJMoa2117175

.

26.

Esrick

EB

,

Lehmann

LE

,

Biffi

A

, et al.

Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease

.

N Engl J Med

.

2021

;

384

(

3

):

205

-

215

.

doi:10.1056/NEJMoa2029392

.

27.

Hsieh

MM

,

Bonner

M

,

Pierciey

FJ

, et al.

Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease

.

Blood Adv

.

2020

;

4

(

9

):

2058

-

2063

.

doi:10.1182/bloodadvances.2019001330

.

28.

Goyal

S

,

Tisdale

J

,

Schmidt

M

, et al.

Acute myeloid leukemia case after gene therapy for sickle cell disease

.

N Engl J Med

.

2022

;

386

(

2

):

138

-

147

.

doi:10.1056/NEJMoa2109167

.

29.

Jones

RJ

,

DeBaun

MR

.

Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither

.

Blood

.

2021

;

138

(

11

):

942

-

947

.

doi:10.1182/blood.2021011488

.

30.

Leonard

A

,

Tisdale

JF

.

A pause in gene therapy: reflecting on the unique challenges of sickle cell disease

.

Mol Ther

.

2021

;

29

(

4

):

1355

-

1356

.

doi:10.1016/j.ymthe.2021.03.010

.

31.

Seminog

OO

,

Ogunlaja

OI

,

Yeates

D

,

Goldacre

MJ

.

Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study

.

J R Soc Med

.

2016

;

109

(

8

):

303

-

309

.

doi:10.1177/0141076816651037

.

32.

Brunson

A

,

Keegan

THM

,

Bang

H

,

Mahajan

A

,

Paulukonis

S

,

Wun

T.

Increased risk of leukemia among sickle cell disease patients in California

.

Blood

.

2017

;

130

(

13

):

1597

-

1599

.

doi:10.1182/blood-2017-05-783233

.

33.

Pincez

T

,

Lee

SSK

,

Ilboudo

Y

, et al.

Clonal hematopoiesis in sickle cell disease

.

Blood

.

2021

;

138

(

21

):

2148

-

2152

.

doi:10.1182/blood.2021011121

.

34.

Lee

B-C

,

Lozano

R-J

,

Dunbar

C-E

.

Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells

.

Mol Ther

.

2021

;

29

(

11

):

3205

-

3218

.

doi:10.1016/j.ymthe.2021.09.001

.

35.

Cradick

TJ

,

Fine

EJ

,

Antico

CJ

,

Bao

G.

CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity

.

Nucleic Acids Res

.

2013

;

41

(

20

):

9584

-

9592

.

doi:10.1093/nar/gkt714

.

36.

AlJanahi

AA

,

Lazzarotto

CR

,

Chen

S

, et al.

Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques

.

Mol Ther

.

2022

;

30

(

1

):

209

-

222

.

doi:10.1016/j.ymthe.2021.06.016

.

37.

Leibowitz

ML

,

Papathanasiou

S

,

Doerfler

PA

, et al.

Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing

.

Nat Genet

.

2021

;

53

(

6

):

895

-

905

.

doi:10.1038/s41588-021-00838-7

.

38.

Schiroli

G

,

Conti

A

,

Ferrari

S

, et al.

Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response

.

Cell Stem Cell

.

2019

;

24

(

4

):

551

-

565.e8565e8

.

doi:10.1016/j.stem.2019.02.019

.

39.

Haapaniemi

E

,

Botla

S

,

Persson

J

,

Schmierer

B

,

Taipale

J.

CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response

.

Nat Med

.

2018

;

24

(

7

):

927

-

930

.

doi:10.1038/s41591-018-0049-z

.

40.

Enache

OM

,

Rendo

V

,

Abdusamad

M

, et al.

Cas9 activates the p53 pathway and selects for p53-inactivating mutations

.

Nat Genet

.

2020

;

52

(

7

):

662

-

668

.

doi:10.1038/s41588-020-0623-4

.

41.

Graphite Bio announces voluntary pause of phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease

. https://ir.graphitebio.com/press-releases/detail/84/graphitebio-announces-voluntary-pause-of-phase-12-cedar. Accessed

5

May

2023

.

42.

Frangoul

H

,

Locatelli

F

,

Bhatia

M

, et al.

Efficacy and safety of a single dose of exagamglogene autotemcel for severe sickle cell disease

.

Blood

.

2022

;

140

(

suppl 1

):

29

-

31

.

doi:10.1182/blood-2022-162353

43.

Kingwell

,

K.

First CRISPR therapy seeks landmark approval

.

Nat Rev Drug Discov

.

2023

;

22

(

5

):

339

-

341

. Accessed

5

May

2023

.

44.

Alavi

A

,

Krishnamurti

L

,

Abedi

M

, et al.

Preliminary safety and efficacy results from Precizn-1: an ongoing phase 1/2 study on zinc finger nuclease- modified autologous CD34+ HSPCs for sickle cell disease (SCD)

.

Blood

.

2021

;

138

(

suppl 1

):

2930

.

45.

Alavi

A

,

Abedi

M

,

Parikh

S

, et al.

Interim safety and efficacy results from a phase 1/2 study of zinc finger nuclease-modified autologous hematopoietic stem cells for sickle cell disease (PRECIZN-1)

.

Blood

.

2022

;

140

(

suppl 1

):

4907

-

4909

.

doi:10.1182/blood-2022-163725

46.

Sharma

A

,

Boelens

JJ

,

Cancio

MI

, et al.

Treatment of individuals with severe sickle cell disease with OTQ923, an autologous, ex vivo, CRISPR/Cas9- edited, CD34+ hematopoietic stem and progenitor cell product, leads to durable engraftment and fetal hemoglobin induction

.

Blood

.

2022

;

140

(

suppl 1

):

1906

-

1908

.

doi:10.1182/blood-2022-166254

.

. https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fourth-quarter-and-full-year-5. Accessed

47.

Intellia Therapeutics

.

Intellia Therapeutics announces fourth quarter and full-year 2022 financial results and highlights recent company progress

.

2023

5

May

2023

.

48.

Leonard

A

,

Sharma

A

,

Uchida

N

, et al.

Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease

.

Blood Adv

.

2021

;

5

(

9

):

2403

-

2411

.

doi:10.1182/bloodadvances.2021004232

.

49.

Czechowicz

A

,

Palchaudhuri

R

,

Scheck

A

, et al.

Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation

.

Nat Commun

.

2019

;

10

(

1

):

617

.

doi:10.1038/s41467-018-08201-x

.

50.

Chhabra

A

,

Ring

AM

,

Weiskopf

K

, et al.

Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy

.

Sci Transl Med

.

2016

;

8

(

351

):

351ra105

.

doi:10.1126/scitranslmed.aae0501

.

51.

Kwon

H-S

,

Logan

A-C

,

Chhabra

A

, et al.

Anti-human CD117 antibody- mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice

.

Blood

.

2019

;

133

(

19

):

2104

-

2108

.

doi:10.1182/blood-2018-06-853879

.

52.

Mondal

N

,

Harmon

A

,

Budak

E

, et al.

Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): paired HSC epitope engineering and upregulation of fetal hemoglobin for antibody-mediated autologous hematopoietic stem cell therapy conditioning for the treatment of hemoglobinopathies

.

Blood

.

2022

;

140

(

suppl 1

):

4487

-

4488

.

doi:10.1182/blood-2022-169120

.

53.

Chu

SH

,

Budak

E

,

Mondal

N

, et al.

Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): paired HSC epitope engineering and direct editing of sickle allele for antibody-mediated autologous hematopoietic stem cell therapy conditioning for the treatment of sickle cell disease

.

Blood

.

2022

;

140

(

suppl 1

):

10213

-

10214

.

doi:10.1182/blood-2022-169257

.

54.

Li

C

,

Wang

H

,

Georgakopoulou

A

,

Gil

S

,

Yannaki

E

,

Lieber

A.

In vivo HSC gene therapy using a bi-modular HDAd5/35++ vector cures sickle cell disease in a mouse model

.

Mol Ther

.

2021

;

29

(

2

):

822

-

837

.

doi:10.1016/j.ymthe.2020.09.001

.

55.

Bradt

P SE

,

Synnott

PG

,

Chapman

R

,

Beinfeld

M

,

Rind

DM

,

Pearson

SD

.

Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value

. Institute for Clinical and Economic Review.

January

23

,

2020

. https://icer.org/wp-content/uploads/2020/10/ICER_SCD_Evidence-Report_031220-FOR-PUBLICATION.pdf. Accessed

5

May

2023

.

56.

Coquerelle

S

,

Ghardallou

M

,

Rais

S

, et al.

Innovative curative treatment of beta thalassemia: cost-efficacy analysis of gene therapy versus allogenic hematopoietic stem-cell transplantation

.

Hum Gene Ther

.

2019

;

30

(

6

):

753

-

761

.

doi:10.1089/hum.2018.178

.

57.

Gillmore

JD

,

Gane

E

,

Taubel

J

, et al.

CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis

.

N Engl J Med

.

2021

;

385

(

6

):

493

-

502

.

doi:10.1056/NEJMoa2107454

.

58.

Banda

O

,

Alameh

M-G

,

Jung

S

,

Weissman

D

,

Rivella

S

,

Kurre

P.

Direct delivery of mRNA-loaded lipid nanoparticles to the hematopoietic stem cell niche

.

Blood

.

2022

;

140

(

suppl 1

):

4923

-

4924

.

doi:10.1182/blood-2022-159085

.

59.

Li

C

,

Georgakopoulou

A

,

Newby

GA

, et al.

In vivo HSC prime editing rescues sickle cell disease in a mouse model

.

Blood

.

2023

;

141

(

17

):

2085

-

2099

.

doi:10.1182/blood.2022018252

.